EMBARGOED FOR RELEASE: 3 P.M. (CT), FRIDAY, DECEMBER 26, 2014
Media Advisory: To contact author Peter Torre, Ph.D., please call 619-379-8594 or email email@example.com
To place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archotol.jamanetwork.com/article.aspx?doi=10.1001/jamaoto.2014.3302
JAMA Otolaryngology-Head & Neck Surgery
Adults with the human immunodeficiency virus (HIV+) had poorer lower- and higher-frequency hearing than adults without HIV infection, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.
The relationship between HIV and hearing loss in the era of highly active antiretroviral therapy (HAART) has not been investigated thoroughly, according to the study background.
Peter Torre III, Ph.D., of San Diego State University, California, and coauthors evaluated pure-tone hearing thresholds among 262 men (117 HIV+) and 134 women (105 HIV+). The men had an average age of 57 years and the women were an average age of nearly 48.
The authors found that high-frequency pure-tone average (HPTA) and low-frequency (LPTA) were significantly higher (i.e. poorer hearing) for HIV+ adults compared with HIV- adults for the better ear. The results were independent of long-term exposure to antiretroviral medications, current CD4+ cell count and HIV viral load.
“To our knowledge, this is the first study to demonstrate that HIV+ individuals have poorer hearing across the frequency range after many other factors known to affect hearing have been controlled for,” the study concludes.
(JAMA Otolaryngol Head Neck Surg. Published online December 26, 2014. doi:10.1001/.jamaoto.2014.3302. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: This research was supported by the National Institute on Deafness and Other Communication Disorders, National Institutes of Health, and other sources. Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email firstname.lastname@example.org.